Brimapitide

Description	Brimapitide is a protease resistant, potent inhibitor specific for JNK (JNK1, JNK2 and JNK3). L-JNKi 1 does not directly affect kinase activity e.g. by competing with the ATP-binding site of the protein kinase, rather L-JNKi1 inhibits the interaction between JNK and its substrate, resulting in a JNK K.O. phenotype. In contrast to pure diffusion they are actively transported into cells, where they remain until their proteolytic degradation. The c-Jun N-terminal kinases (JNK1, 2, 3), members of the mitogen-activated protein kinase (MAPK) superfamily, are activated by a wide variety of extracellular stimuli such as inflammatory cytokines, heat shock and ischemia.
Pathways	MAPK Pathway
Targets	JNK

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.